You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
Ravgen has alleged that several leading NGS-based non-invasive prenatal testing and oncology assays infringe two patents held by the firm.
CareDx first sued Natera in March 2019 for infringing two of its patents, then amended the suit a year later to add a third patent.
Williams v Quest/Athena struck a nerve with the genetic testing community by probing what the standard of care is and ought to be for variant classification.
Last month, the court also ordered two separate patent lawsuits filed by Natera against ArcherDx this year to be consolidated into one.
Natera previously filed infringement lawsuits against ArcherDx around four other patents related to cell-free DNA detection in oncology.
Magnolia said that the court found that its product claims were not misleading. However, Kurin's CEO said that over the years, Magnolia has displayed a pattern of exaggeration.
The US DOJ alleged that the company conspired to "artificially delay" ordering its MammaPrint test in order to circumvent Medicare's 14-day rule.
In January a federal court unsealed a False Claims Act suit from an industry insider that alleges a Myriad subsidiary engaged in a fraudulent kickback scheme.
Illumina had sought to exclude the Harmony test from the US Market, while Ariosa had sought to overturn the jury verdict with a post-trial maneuver.
The plaintiffs allege that TAI's heart transplant rejection test MyTAIHeart infringes on their patent for the non-invasive diagnosis of graft rejection.